3 research outputs found
Cell-Based Therapy Of Human Adipose- Derived Mesenchymal Stem Cell Expressing Angiopoietin-1 In An Experimental Model Of Airway Inflammation
Cell-based therapy of mesenchymal stem cells (MSCs) has been shown to enhance the endogenous repair process by increasing the limited regenerative capacity of the lung in chronic lung disorders as well as following injury. However, the underlying cellular and molecular mechanisms of MSCs to enhance airway regeneration and repair are remain unclear. This study was aimed to investigate the effect of delivering human adipose-derived MSCs (hAD-MSCs) alone and in combination with vasculoprotective factor, the ANGPT1, by aerosol technique in a rabbit model of asthma related-airway inflammation
A comparative study of non-viral gene delivery techniques to human adipose-derived mesenchymal stem cell
Mesenchymal stem cells (MSCs) hold tremendous potential for therapeutic use
in stem cell-based gene therapy. Ex vivo genetic modification of MSCs with beneficial
genes of interest is a prerequisite for successful use of stem cell-based therapeutic
applications. However, genetic manipulation of MSCs is challenging because they are
resistant to commonly used methods to introduce exogenous DNA or RNA. Herein we
compared the effectiveness of several techniques (classic calcium phosphate precipitation,
cationic polymer, and standard electroporation) with that of microporation technology
to introduce the plasmid encoding for angiopoietin-1 (ANGPT-1) and enhanced green
fluorescent protein (eGFP) into human adipose-derived MSCs (hAD-MSCs). The
microporation technique had a higher transfection efficiency, with up to 50% of the viable
hAD-MSCs being transfected, compared to the other transfection techniques, for which
less than 1% of cells were positive for eGFP expression following transfection.
The capability of cells to proliferate and differentiate into three major lineages
(chondrocytes, adipocytes, and osteocytes) was found to be independent of the technique
used for transfection. These results show that the microporation technique is superior to the
others in terms of its ability to transfect hAD-MSCs without affecting their proliferation
and differentiation capabilities. Therefore, this study provides a foundation for the selection of techniques when using ex vivo gene manipulation for cell-based gene therapy
with MSCs as the vehicle for gene delivery
Recommended from our members
The use of mesenchymal stromal cells in treatment of lung disorders
The therapeutic use of mesenchymal stromal cells (MSCs) represents a promising alternative clinical strategy for treating acute and chronic lung disorders. Several pre-clinical reports demonstrated that MSCs can secrete multiple paracrine factors and that their immunomodulatory properties can support endothelial and epithelial regeneration, modulate the inflammatory cascade, and protect lungs from damage. The effects of MSC transplantation into patients suffering from lung diseases should be fully evaluated through careful assessment of safety and associated risks, which is a prerequisite for translation of pre-clinical research into clinical practise. In this article we summarise the current status of pre-clinical research and review initial MSC-based clinical trials for treating lung injuries and lung disorders